Proton Beam Therapy, a revolution in radiation oncology, brings a new ray of hope to cancer patients

A 12-yr-old boy from Bengaluru was successfully treated with proton beam therapy for pineal gland brain tumour

Bengaluru, March 29, 2023: With the mission to provide the most comprehensive and advanced cancer care in India, Apollo Proton Cancer Centre (APCC), South Asia’s first and only proton therapy centre, has successfully treated a 12-year-old boy from Bengaluru with proton beam therapy (PBT) for pinealoblastoma-a rare type of cancer that occurs in the pineal gland of the brain. The pineal gland is located in the centre of the brain and it produces a hormone called melatonin, which plays a role in the natural sleep-wake cycle of the human body.

Venkata Srisaravana Vemula, from Bengaluru was diagnosed with pinealoblastoma in Oct 2018. After undergoing an endoscopic third ventriculostomy and biopsy, he was started on chemotherapy HEADSTART III protocol. The patient received five cycles of chemotherapy and was consulted at APCC, Chennai, for further treatment. After a thorough check-up and evaluation of his medical reports, the experts at APCC planned for craniospinal radiation (CSI) using proton beam therapy followed by tumour bed boost using IMRT (photons). The patient was immobilized using a customized headrest and 4 clamp mould for radiation planning. After quality assurance checks, clinicians adviced for radiation therapy which started on 25 March 2019. The treatment significantly reduced the size of the pineoblastoma lesion. The family was counselled in detail regarding treatment plans and the benefits of proton beam therapy in reducing acute and late toxicities.

Globally around 330,000 children and adults were diagnosed with cancer of the Central Nervous System(CNS) in a year and the number continues to rise along with the increasing mortality rate of brain tumours. In India, CNS cancer ranges from 5 to 10 per 100,000 people with a rising trend and accounts for 2% of cancer.

The International Association of Cancer Registries (IARC) states that there are around 28,000 cases of brain cancer reported in India every year and alarmingly 24,000 people die due to brain tumours annually. So far, APCC has treated over 300 cases of brain tumours, 22 of which are from Bengaluru.

Mr. Dinesh Madhavan, President, Group Oncology and International, Apollo Hospitals Enterprise Ltd, said, “We are extremely proud of master Venkata’s win over cancer and the team at the Apollo Proton Cancer Centre, who worked tirelessly to extend the best treatment possible & care to him. This case demonstrates the efficacy of proton therapy in the treatment of cancer, particularly when combined with other modalities. We remain committed to advancing the field of cancer treatment and investing in cutting-edge technology such as proton therapy, to ensure that our patients receive the best possible outcomes.”

Dr. Srinivas Chilukuri, Senior Consultant, Radiation Oncology, Apollo Proton Cancer Centre, Chennai said, “Master Venkata’s response to the treatment for pinealoblastoma has been remarkable, demonstrating the efficacy of the comprehensive treatment plan. In this case, the tumour was in the pineal gland, a risky location in the centre of the brain, and proton therapy helps deliver highly focused protons, spot-by-spot and layer-by-layer, to disrupt the tumour and target radiation to the size and shape of the tumour without harming the surrounding healthy tissues. It has been shown to be effective in curing or controlling many cancers, as well as reducing both immediate and long-term side effects of treatment, resulting in improved survival and survivorship.”

“The success of this case can be attributed to the patient’s courage and resilience, as well as the tireless efforts of our team. We are honoured to have been able to contribute to Venkata’s care and well-being. We remain committed to providing our patients with the best cancer treatment options possible,” said, Dr. Chilukuri.

While speaking about his son’s treatment, Mr Satish Kumar Vemula, father of Venkata Srisaravana Vemula, said, “I am grateful to APCC and the entire medical team for their contributions to my son’s treatment & his recovery. Doctors provided us with the best possible care & treatment, and their support throughout the treatment was invaluable. I’d like to thank them for their dedication and hard work, as well as for being a source of strength and encouragement throughout this ordeal. I’m looking forward to my son’s return to normalcy.”

Mr. Navadiya Jemin Mansukhbhai, who was treated at APCC, said, “My treatment for cervico- medullary pilocytic astrocytoma at APCC was a holistic experience. The doctors and clinical staff were very considerate of my choices and had a detailed treatment plan in place. Intensity- modulated proton therapy was a game changer in my battle with a brain tumour. The environment was such that it didn’t feel like a hospital.”

The major advantage of proton therapy treatment is that protons slowly deposit their energy as they travel towards the cancerous tumour and deposit most of the radiation dose directly in the tumour without damaging the body further thus maintaining healthy tissues and organs without any complications. Proton therapy has been shown to have excellent local control of various cancers located in some of the most difficult areas such as skull-base regions of the body which are otherwise difficult to treat. The latest breakthroughs in this technology including pencil beam scanning, highly precise image guidance and tremendous refinements in the machine set up have led to the adoption of this technology throughout the world in hospital settings in the last few years.

Proton therapy is being encouragingly adopted for the treatment of various cancers such as brain and spine tumours, skull base tumours, oral cancers, gastro-intestinal cancers, bone and soft tissue tumours, breast cancers, thoracic cancers (lung cancer), genitourinary cancers (prostate cancer) and predominantly in paediatric cancers except for leukaemia.

#WinningOverCancer

City Today News – 9341997936

CONCERT FOR CANCER FREE SOCIETY-26TH FEBRUARY

The Ministry of Human Resource Development, Govt. of India, based on the recommendations of the University Grants Commission granted recognition to Yenepoya University Trust, A Deemed to be University status under Section 3A of the UGC Act, 1956 in the year 2008 with Yenepoya Dental College as its constituent college. Over a span of 15 years, the University has now grown to include 10 constituent units with nearly 7000 students pursuing various courses related to health and general education. Currently the university is accredited by NAAC with A+ Grade (second cycle) and it is constantly within top 100 universities of the country as per NIRF rankings published by the Ministry of HRD, Govt. of India. The university offers more than 100 UG, PG, PhD, super speciality and fellowship programmes. Currently the university is functioning from 5 different campuses covering a total area of nearly 100 acres in Mangalore. In addition to Academics, the university also offers excellent services related to research through state of the art research centre and Incubation Centre. For skill development of the students highly sophisticated skill lab and surgical training labs are also available.

Yenepoya Medical College hospital is a teaching hospital attached to the medical college with more than 1100 beds offers free and highly subsidised speciality and superspeciality services to the needy. The hospital is empanelled under most of the Government Insurance Schemes and the patients covered by these schemes are treated totally free of cost. Apart from the general services, the hospital also offers premium services including Robotic Surgery, Renal Transplant, Cardiac Procedures and IVF facilities to name a few.

The hospital has been serving cancer patients since the last decade at very affordable costs, with its expert team and highly advanced equipments. Looking at our achievements, TATA Trusts Mumbai came forward to support us to establish Zulekha Yenepoya Institute of Oncology, a comprehensive centre for the treatment and care of cancer patients. The facility has a built in area of 36000 sq.ft. The Centre has a state of the art true beam

Radiotherapy machine for targeted and precise approach to cancer and a brachytherapy machine. The building also has a nuclear medicine facility including PET, CT scan, SPECT, day care chemotherapy facility and dedicated area for pain and palliative services. The Centre also has a dedicated mobile wellness clinic supported by Rotary International for preventive oncology and early detection of non communicable diseases including cancer.

We at Zulekha Yenepoya Institute of Oncology believe in leaving no stone unturned when it comes to cancer care. The university has initiated many activities as a part of making Cancer Care affordable to the patients. As a part of this initiative, a musical concert has been proposed in Dr.Ambedkar Bhavan, Millers Road, Bangalore, on Sunday, 26th February 2023 from 4pm to 8pm as a fund raising activity. Many dignitaries and officials will be part of this event and invites have been sent to like minded people, who want to be the part of this noble initiative to support patients suffering from cancer. The entire amount raised through this activity will be used to develop a corpus fund to the support and care of cancer patients. The university requests everyone to support this noble cause by actively taking part in this event and help us to serve the society better.

City Today News – 9341997936

BLOOD CANCER SURVIVOR MEETS HIS LIFESAVER FOR THE FIRST TIME

Mandeep, a techie from Bengaluru reinstates faith in humanity by donating his stem cells to savea blood cancer patient

Bengaluru, 9 February 2023: A surreal story unfolded as Mandeep, a blood cancer survivor met his lifesaver also named Mandeep for the first time. An event was organised by DKMS BMST Foundation India, to mark World Cancer Day and celebrate the first meeting between the stem cell donor and his recipient.

Mandeep, blood cancer survivor, 35-year-old, a farmer from Punjab was diagnosed with Chronic Myeloid Leukemia in 2009. Unfortunately, though Mandeep was advised for a stem cell transplant he could not find a Human Leukocyte Antigen (HLA) matched stem cell donor within his family. Mandeep had to wait for over 3 years before an HLA matching unrelated donor was identified with the help of DKMS BMST Foundation India and he underwent stem cell transplant in January 2020.

Mandeep (blood cancer survivor), said, “Cancer was a big shock to me and everyone around me. I was healthy and doing well, when suddenly everything just crashed. I was advised a stem cell transplant by the doctors, but we could not find any matching donor from my family. After a colossal struggle of over a decade against cancer, my struggle ended when a matching unrelated donor was identified with the help of DKMS-BMST. I was treated under the expertise of Dr. Dinesh Bhurani, Director, Department of Haemato-oncology & Bone Marrow Transplantation, at Rajiv Gandhi Cancer Institute and Research Center, New Delhi. And it was amazing that I was able to get the transplant done in January 2020. Today, I am completely cured. I have waited for over two years to meet my genetic twin, whose stem cell donation saved my life, and coincidently he is my namesake. I am very grateful to Mandeep (Donor), because of him, I got a second chance at life.”

As per the International guidelines, the identity of both the blood stem cell donor and recipient are kept anonymous for a period of two years and thereafter depending on their interest they are introduced to each other.

Mandeep (Stem Cell Donor, 39-Year-old) said, “It was truly wonderful to meet with Mandeep (blood cancer survivor). After my stem cell donation in December 2019, I had always wondered about the well-being of my stem cell recipient, and finally today we get to meet. My wife is also a cancer patient, and I do understand the pain and agony of the family members. I registered as a stem cell donor in a registration drive organised by DKMS-BMST in my office in 2018. After being identified as a match, DKMS-BMST team guided me in every step and I donated my stem cells in a hassle-free manner.”

Patrick Paul, CEO, DKMS-BMST Foundation india, said “It is always a very happy occasion for us when we introduce the cancer survivor with their lifesaver for the first time. So far, DKMS-BMST has registered over 80,000 potential donors and has helped 80 patients in India with a second chance at life. It is our endeavour to provide blood cancer and blood disorder patients with a second chance at life. India has one of the highest burdens of these life-threatening diseases in the world, and every year, over one lakh new patients are being diagnosed. These diseases are one of the leading causes of cancer-related deaths among children. Most people are unaware that a life-threatening disease like blood cancer can be treated by a stem cell transplant.”

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, informed, “Stem cell transplantation from a related or unrelated donor is a standard treatment for blood cancer and disorder patients. This stem cell transplant after 3 to 4 months of chemotherapy helps the patients to recover from the disease. Without the stem cell transplant, the chances of relapse are quite high. When matching donor is not available within the family, a search is carried out with help of registries like DKMS -BMST to find a matching unrelated donor, just like in the case of Mandeep. Therefore, the need of the hour is to increase awareness and encourage more Indians to register as stem cell donors so that more lives can be saved.”

Today, more than 40 million potential unrelated donors are listed worldwide with stem cell donor centres and registries. Of which only 0.04% are Indians. This situation can only be changed by recruiting many potential blood stem cell donors from India. If you’re between 18 and 55 and in general good health, take the first step to register as a blood stem cell donor by ordering your home swab kit at http://www.dkms-bmst.org/register

City Today News – 9341997936

DKMS BMST Foundation India and Acharya Institute of Technology, Bengaluru joined hands to help blood cancer patients

Over 300 students of AIT and professors registered as stem cell donors

Bengaluru, 10th January 2023: DKMS BMST Foundation India, a non-profit organization dedicated to fight against blood cancer, organised a blood stem cell donor registration drive at Acharya Institute of Technology, Bengaluru (AIT) organized by Department of MBA, in association with NSS, AIT. Over 300 students including NSS students registered themselves as potential lifesavers. 

Over the next 2 years, DKMS BMST Foundation India and Acharya Institute of Technology will work closely together to help blood cancer patients by registering more potential stem cell donors and raise awareness about this noble cause. 

Patrick Paul, CEO, DKMS BMST Foundation India, said, “Often a blood stem cell transplant from a matching stem cell donor is the only chance at survival for blood cancer and blood disorder such as Thalassemia and Aplastic Anemia patients. A successful blood stem cell transplant needs a perfect HLA tissue match. Every year over 1 lakh people are diagnosed with such life-threatening diseases in India and with the increasing burden, more and more Indian patients are looking for matching stem cell donors., we aim to raise awareness about blood stem cell donation through this association with AIT.  we hope that the student community will further strengthen our mission and help save more lives.” 

Dr. Rajath Hegde M M Principal, Acharya Institute of Technology (AIT), said, “Today’s younger generation have huge potential and a great zeal to empower and encourage others to contribute to a noble cause. After all, saving a life is as important as giving a new life. We as an institution are so proud to be a part of this cause and will continue help raise awareness amongst public to come forward and register as a stem cell donor”.

Prof. Marigowda, Vice-Principal, Acharya Institute of Technology (AIT), said, “We support the foundation in all possible ways. We are inspired by their mission of giving second chance at life to blood cancer patients and we hope that our association can help many more patients in their fight against such life-threatening diseases.  I appreciate the entire student coordinators and volunteers and DKMS-BMST for the effort they are putting in this noble cause.”

The blood cancer awareness programme and donor registration drive were organized by Dr. Juin Choudhury, HOD-MBA and coordinated by Dr. Nijaguna G, Prof. Monica M, Assistant Professor, Dr. Prashanth KP, NSS officer, Prof. Channakeshava and Dr. Sanman, NSS Coordinators. The team of Students volunteers were identified and trained to drive the students to attend the programme. 

During the registration drive one of the students said “I am feeling extremely happy, and proud of the fact that I have registered as a potential stem cell donor by a simple process of giving my swab samples. I am also delighted that that so many students have come forward and registered for this worthy cause. DKMS-BMST very clearly elucidated the whole process, which has given us complete clarity. I am hopeful that someday I may also get a chance to save a precious life. This is a great cause, and I will continue to volunteer and raise awareness on blood stem cell donation.”

Every 5 minutes, someone in India is diagnosed with blood cancer, or blood disorders like Thalassemia or Aplastic Anemia, which is becoming a major public health challenge in our country. A blood stem cell transplant from an HLA matched donor is an effective treatment for long term management of the disease and for improving the quality of life of the patient. However, 70% of the patients are unable to receive a transplant due to unavailability of matching blood stem cell donor from within their family and are dependent on an unrelated HLA matched donor. With very few individuals signing up as potential blood stem cell donors, the probability of finding an HLA matching donor is extremely difficult in most cases.  Therefore, it is important that more and more people of Indian ethnicity come forward and register as a potential stem cell donor.

Registration process:

Interested citizens between 18-55 age-group can register at:  dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process: 

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home. 

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit. 

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Your blood stem cells will be collected from the bloodstream via Peripheral Blood Stem Cell Collection process, which is similar to a blood platelet donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient process. 

City Today News – 9341997936

ಪ್ರಪಂಚದಲ್ಲಿ ಮೊದಲ ಬಾರಿಗೆ, ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರವು ಮುಖದ ನರವಾದ ಶ್ವಾನೋಮಾದ ಎಂಡೋಸ್ಕೋಪಿಕ್ ಟ್ರಾನ್ಸ್‌ಕೆನಲ್ ಹೊರತೆಗೆಯುವಿಕೆಯನ್ನು ಮಾಡುತ್ತದೆ.

ಡಾ ಸತೀಶ್ ನಾಯರ್, ತಲೆ ಮತ್ತು ಕುತ್ತಿಗೆಯ ಶಸ್ತ್ರಚಿಕಿತ್ಸಾತಜ್ಞರು, ಕಿವಿಯ ಸಂಪೂರ್ಣ ಕಾರ್ಯವನ್ನು ಉಳಿಸಿಕೊಳ್ಳಲು 3 ವಿಶಿಷ್ಟ ತಂತ್ರಗಳ ಬಳಕೆಯನ್ನು ವಿವರಿಸುತ್ತಾರೆ.
ಬೆಂಗಳೂರು, 24 ನವೆಂಬರ್ 2022: ಅಪರೂಪದ ಕ್ಯಾನ್ಸರ್ ಪ್ರಕರಣಗಳ ಚಿಕಿತ್ಸೆಗಾಗಿ ಹೊಸ ತಂತ್ರಗಳನ್ನು ಆವಿಷ್ಕರಿಸುವತ್ತ ಗಮನಹರಿಸುವುದರೊಂದಿಗೆ, ಬೆಂಗಳೂರಿನ ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರವು ಮುಂದುವರಿದ ಆರೈಕೆಯೊಂದಿಗೆ ಕ್ಯಾನ್ಸರ್ ಹೋರಾಟದಲ್ಲಿ ಮುಂಚೂಣಿಯಲ್ಲಿದೆ.

ಕ್ಯಾನ್ಸರ್ ನಿರ್ವಹಣೆಯಲ್ಲಿನ ಉದಯೋನ್ಮುಖ ಪ್ರವೃತ್ತಿಗಳು ಮತ್ತು ನಿರ್ಲಿಪ್ತವಾದ ಅಭ್ಯಾಸದ ಮೇಲೆ ಅವುಗಳ ಪ್ರಭಾವವನ್ನು ಉದ್ದೇಶಪೂರ್ವಕವಾಗಿ ಪರಿಗಣಿಸುವುದು ಅಪೋಲೋ ಅವರ ದೃಷ್ಟಿ, ಹೀಗಾಗಿ 147 ದೇಶಗಳ 3.5 ಶತಕೋಟಿ ಜನರಿಗೆ ಭರವಸೆಯ ಕಿರಣವನ್ನು ತರುತ್ತದೆ.
ನಮ್ಮ ಗಮನವು ಚುರುಕಾದ, ಸುರಕ್ಷಿತ ಮತ್ತು ಹೆಚ್ಚು ಪರಿಣಾಮಕಾರಿ ಚಿಕಿತ್ಸೆಗಳ ಮೇಲೆ ಕೇಂದ್ರೀಕೃತವಾಗಿರುವುದರಿಂದ, ಬೆಂಗಳೂರಿನ ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರದ ಗ್ರಂಥಿ ಶಾಸ್ತ್ರಜ್ಞರು ಇತ್ತೀಚೆಗೆ ಮುಖದ ನರ ಶ್ವಾನೋಮಾ ಚಿಕಿತ್ಸೆಯಲ್ಲಿ ಪ್ರಗತಿಯನ್ನು ಸಾಧಿಸಿದ್ದಾರೆ.

ಡಾ ಸತೀಶ್ ನಾಯರ್, ಹಿರಿಯ ಸಲಹೆಗಾರರು, ಇಎನ್ ಟಿ ಮತ್ತು ತಲೆ ಮತ್ತು ಕುತ್ತಿಗೆ ಗ್ರಂಥಿ ಶಾಸ್ತ್ರ, ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರ, ಬೆಂಗಳೂರು, ಇವರ ಜೊತೆಗೆ ವೈದ್ಯಕೀಯ ತಜ್ಞರ ತಂಡವು ಕಳೆದ ಎರಡು ವರ್ಷಗಳಿಂದ ಬಲಬದಿಯ ಮುಖದ ದೌರ್ಬಲ್ಯದಿಂದ ಬಳಲುತ್ತಿರುವ 35 ವರ್ಷದ ರೋಗಿಯ ಮೇಲೆ ಮುಖದ ನರ ಶ್ವಾನ್ನೋಮಾದ ಎಂಡೋಸ್ಕೋಪಿಕ್ ಟ್ರಾನ್ಸ್ ಕೆನಾಲ್ ಛೇದನವನ್ನು ನಡೆಸಿತು. ಕಿವಿಯ ಸಂಪೂರ್ಣ ಕಾರ್ಯವನ್ನು ಉಳಿಸಿಕೊಳ್ಳಲು ತಲೆ ಮತ್ತು ಕುತ್ತಿಗೆ, ಲ್ಯಾಟರಲ್ ಸ್ಕಲ್-ಬೇಸ್ ಅಪ್ರೋಚ್ ಮತ್ತು ಎಂಡೋಸ್ಕೋಪಿಕ್ ತಂತ್ರಗಳ ತತ್ವಗಳನ್ನು ಒಟ್ಟಿಗೆ ಬಳಸಿದ್ದು ಇದು ಪ್ರಪಂಚದಲ್ಲಿ ಮೊದಲ ಬಾರಿಗೆ ನಡೆಸಲಾಗಿದೆ.

ತಂಡವು ಓಟೋ ಎಂಡೋಸ್ಕೋಪಿಯನ್ನು ಮಾಡಿತು, ಇದು ಹಿಂಭಾಗದ ಚತುರ್ಭುಜದಲ್ಲಿ ಅಖಂಡ ಟೈಂಪನಿಕ್ ಮೆಂಬ್ರೇನ್‌ ನ ಹಿಂದೆ ಗುಲಾಬಿ-ತೆಳು ನಾನ್-ಪಲ್ಸಟೈಲ್ ದ್ರವ್ಯರಾಶಿಯನ್ನು ಬಹಿರಂಗಪಡಿಸಿತು. ಇದರಲ್ಲಿನ ಹೆಚ್ಚಿನ ಪರೀಕ್ಷೆಯು ರೋಗಿಯು ಬಲ-ಬದಿಯ ವಿ ದರ್ಜೆಯ ಕಡಿಮೆ ಮೋಟಾರು ನರಕೋಶದ ಮುಖದ ಪಾರ್ಶ್ವವಾಯು ಮತ್ತು ಟೆಂಪೊರಲ್ ಬೋನ್‌ ನ ಹೆಚ್ಚಿನ-ರೆಸಲ್ಯೂಶನ್ ಕಂಪ್ಯೂಟೆಡ್ ಟೊಮೊಗ್ರಫಿಯ ಮುಖದ ನರಗಳ ಹಿಂಭಾಗದ ಕುಲದ ಸವೆತವನ್ನು ಮುಖದ ಗುಪ್ತಸ್ಥಾನಗಳಲ್ಲಿನ ಸಮೂಹದಲ್ಲಿ ಬಹಿರಂಗಪಡಿಸಿತು, ಇದು ಮುಖದ ನರದ ಶ್ವಾನೋಮಾವನ್ನು ಸೂಚಿಸುತ್ತದೆ.

ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯು ಎರಡು ಗಂಟೆಗಳ ಕಾಲ ನಡೆಯಿತು, ಇದರಲ್ಲಿ ವೈದ್ಯರ ತಂಡವು ಹೆಚ್ಚಿನ ಆರಿಕ್ಯುಲರ್ ನರವನ್ನು ಬಳಸಿಕೊಂಡು ಕೇಬಲ್ ಕಸಿ ಮಾಡುವ ಮೂಲಕ ಮುಖದ ನರವಾದ ಶ್ವಾನೋಮಾದ ಎಂಡೋಸ್ಕೋಪಿಕ್ ಟ್ರಾನ್ಸ್ ಕೆನಾಲ್ ಛೇದನವನ್ನು ನಡೆಸಿತು. ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ನಂತರದ ಎರಡನೇ ದಿನದಂದು ಯಾವುದೇ ತೊಂದರೆಗಳಿಲ್ಲದೆ ರೋಗಿಯನ್ನು ಬಿಡುಗಡೆ ಮಾಡಲಾಯಿತು.
ಡಾ ಸತೀಶ್ ನಾಯರ್, ಹಿರಿಯ ಸಲಹೆಗಾರರು, ಇಎನ್ ಟಿ ಮತ್ತು ತಲೆ ಮತ್ತು ಕುತ್ತಿಗೆ ಗ್ರಂಥಿ ಶಾಸ್ತ್ರ, ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರ, ಬೆಂಗಳೂರು, ಇವರು ಹೀಗೆ ಹೇಳಿದರು, “ನಾವು ಈ ವಿಶಿಷ್ಟ ಪ್ರಕರಣವನ್ನು ಮೊದಲು ನೋಡಿದಾಗ, ನಮ್ಮ ಮುಂದಿರುವ ಸವಾಲುಗಳನ್ನು ನಾವು ತಿಳಿದುಕೊಂಡಿದ್ದೆವು, ಆದರೆ ಹೊಸ ಯುಗದ ಸುಧಾರಿತ ತಂತ್ರಜ್ಞಾನದಲ್ಲಿನ ವಿಶ್ವಾಸವು ರೋಗಿಗೆ ಅಗತ್ಯವಾದ ಫಲಿತಾಂಶಗಳನ್ನು ನೀಡುವುದನ್ನು ಖಚಿತಪಡಿಸಿತು. ರೋಗನಿರ್ಣಯವು ಮುಖದ ನರವಾದ ಶ್ವಾನೋಮಾ ಸಂಕೀರ್ಣವಾದ ಸ್ಥಾನದಲ್ಲಿದೆ ಮತ್ತು ಮುಖದ ಪಾರ್ಶ್ವವಾಯುವಿಗೆ ಕಾರಣವಾಗುತ್ತದೆ ಎಂದು ಬಹಿರಂಗಪಡಿಸಿತು. ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯು ಕಠಿಣವಾಗಿತ್ತು ಆದರೆ ಸರಿಯಾದ ತಂತ್ರ ಮತ್ತು ಪರಿಣತಿಯೊಂದಿಗೆ, ಮುಖದ ನರವಾದ ಶ್ವಾನೋಮಾದ ಪ್ರಪಂಚದ ಮೊದಲ ಎಂಡೋಸ್ಕೋಪಿಕ್ ಟ್ರಾನ್ಸ್ ಕೆನಾಲ್ ಛೇದನವನ್ನು ನಾವು ಮಾಡಲು ಸಾಧ್ಯವಾಯಿತು. ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ನಂತರ ರೋಗಿಯು ಉತ್ತಮವಾಗಿ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿದ್ದಾರೆ.”
ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ಕುರಿತು ತಮ್ಮ ಆಲೋಚನೆಗಳನ್ನು ಹಂಚಿಕೊಂಡ ಡಾಕ್ಟರ್ ಮನೀಷ್ ಮಟ್ಟೂ, ಮುಖ್ಯ ಕಾರ್ಯನಿರ್ವಾಹಕ ಅಧಿಕಾರಿ, ಅಪೋಲೋ ಆಸ್ಪತ್ರೆಗಳು, ಕರ್ನಾಟಕ ಪ್ರದೇಶ, ಹೀಗೆ ಹೇಳಿದರು, “ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರದಲ್ಲಿ, ನಮ್ಮ ವೈದ್ಯರು ಮತ್ತು ಶಸ್ತ್ರಚಿಕಿತ್ಸಕರ ಕೈಯಲ್ಲಿ ತಮ್ಮ ನಂಬಿಕೆ ಮತ್ತು ಜೀವನವನ್ನು ಇರಿಸುವ ರೋಗಿಗಳಿಗೆ ಅತ್ಯುತ್ತಮ ವಿಶ್ವ ದರ್ಜೆಯ ಚಿಕಿತ್ಸೆಯನ್ನು ಒದಗಿಸುವ ನಮ್ಮ ಧ್ಯೇಯಕ್ಕೆ ನಾವು ಬದ್ಧರಾಗಿದ್ದೇವೆ. ಡಾಕ್ಟರ್ ನಾಯರ್ ಅವರು ಉದ್ದೇಶಿಸಿರುವ ವಿಶಿಷ್ಟ ಪ್ರಕರಣವು ಯಾವುದೇ ಪ್ರಕರಣವನ್ನು ಉತ್ಸಾಹ ಮತ್ತು ಬುದ್ಧಿಶಕ್ತಿಯಿಂದ ಅನುಸರಿಸಿದರೆ, ರೋಗಿಗಳಿಗೆ ಸಾಧ್ಯವಾದಷ್ಟು ಉತ್ತಮ ರೀತಿಯಲ್ಲಿ ಸಹಾಯ ಮಾಡಲು ಪರಿಹಾರಗಳನ್ನು ಕಂಡುಹಿಡಿಯಬಹುದು ಎಂದು ನಮಗೆ ಮನವರಿಕೆ ಮಾಡಿದೆ.”
ಮುಖದ ನರವಾದ ಶ್ವಾನೋಮಾಗಳು ಅಪರೂಪದ ನಿಧಾನವಾಗಿ ಬೆಳೆಯುವ ಗೆಡ್ಡೆಗಳಾಗಿದ್ದು, ಎಲ್ಲಾ ತಾತ್ಕಾಲಿಕ ಮೂಳೆ ಗೆಡ್ಡೆಗಳಲ್ಲಿ 1% ಕ್ಕಿಂತ ಕಡಿಮೆಯಿರುತ್ತವೆ. ಮುಖದ ನರದ 7 ನೇ ಕಪಾಲದ ನರಗಳ ಮೇಲೆ ಶ್ವಾನೋಮಾ ಬೆಳೆಯುತ್ತದೆ. ಇದು ಹಾನಿಕರವಲ್ಲದ ಮತ್ತು ನಿಧಾನವಾಗಿ ಬೆಳೆಯುವ ಗೆಡ್ಡೆಯಾಗಿದೆ. ಇದನ್ನು ಫೇಶಿಯಲ್ ನ್ಯೂರೋಮಾ ಎಂದೂ ಕರೆಯುತ್ತಾರೆ. ಗಡ್ಡೆಯು ಬಾಹ್ಯ ಮತ್ತು ಕಪಾಲದ ನರಗಳ ನರತಂತುಗಳನ್ನು ಸುತ್ತುವರೆದಿರುವ ಶ್ವಾನ್ ಕೋಶಗಳಿಂದ ಉಂಟಾಗುತ್ತದೆ. Cancer.gov ಪ್ರಕಾರ, ಇದು ಜಗತ್ತಿನಾದ್ಯಂತ 200,000 ಕ್ಕಿಂತ ಕಡಿಮೆ ಜನರ ಮೇಲೆ ಪರಿಣಾಮ ಬೀರಿದೆ. ಭಾರತದಲ್ಲಿ, 50,000ದಲ್ಲಿ ಮುಖದ ನರ ಶ್ವಾನೋಮಾದ ಸಂಭವವು 1 ಆಗಿದೆ.
ಅಪೋಲೋ ಕ್ಯಾನ್ಸರ್ ಕೇಂದ್ರ, ಬೆಂಗಳೂರು ಸಮಗ್ರವಾದ, ಬಹು-ಮಾದರಿಯ ಅತ್ಯಾಧುನಿಕ ಕ್ಯಾನ್ಸರ್ ಆರೈಕೆ ಸೌಲಭ್ಯವಾಗಿದ್ದು, ಸಂಘಟಿತ ಬಹುಶಿಸ್ತೀಯ ವಿಧಾನವನ್ನು ಹೊಂದಿದೆ. ಇತ್ತೀಚಿನ ತಂತ್ರಜ್ಞಾನ ಮತ್ತು ಹೆಚ್ಚು ನುರಿತ ಆರೋಗ್ಯ ವೃತ್ತಿಪರರನ್ನು ಒಟ್ಟುಗೂಡಿಸುವುದು ಸೇರಿದಂತೆ, ಎಸಿಸಿ ಬೆಂಗಳೂರು ಎಲ್ಲಾ ಸೂಪರ್ ಸ್ಪೆಷಾಲಿಟಿ ಮತ್ತು ಸೈಟೋಲಜಿ, ಹಿಸ್ಟೋಪಾಥಾಲಜಿ, ಹೆಮಟಾಲಜಿ, ಪೆಥಾಲಜಿ, ಪಿಇಟಿ-ಸಿಟಿ ಸೇರಿದಂತೆ ರೇಡಿಯಾಲಜಿ ಸೇವೆಗಳು, ಪಾಥ್ ಲ್ಯಾಬ್, ಫಿಸಿಯೋಥೆರಪಿ, ರಕ್ತದ ಬ್ಯಾಂಕ್ ಮತ್ತು ಇನ್ನೂ ಅನೇಕ ಸೇವೆಗಳನ್ನು ಸೇರಿದಂತೆ ಎಲ್ಲಾ ಸೂಪರ್ ಸ್ಪೆಷಾಲಿಟಿ ಮತ್ತು ಡಯಾಗ್ನೋಸ್ಟಿಕ್ ಮತ್ತು ಬೆಂಬಲ ಸೇವೆಗಳಿಂದ ಅತ್ಯಾಧುನಿಕ ಬ್ಯಾಕಪ್ ಹೊಂದಿರುವ ಅದ್ವಿತೀಯ ಕ್ಯಾನ್ಸರ್ ಘಟಕದ ವಿಶಿಷ್ಟ ಪ್ರಯೋಜನವನ್ನು ಹೊಂದಿರುತ್ತದೆ.

#ಕ್ಯಾನ್ಸರ್ವಿರುದ್ಧಗೆಲುವು

City Today News – 9341997936